ACY-1215
Phase 1Small molecule
Bristol-Myers SquibbACY-1215 is one of 15 small molecule programs targeting Relapse. It is currently in Phase 1.
1
Indications
8
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
14 competitors in Relapse
#DrugCompanyPhaseTrials
1Camptosar
PfizerPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Epkinly
GenmabPhase 2
Calquence
AstraZenecaPhase 2
Venclexta
AbbViePhase 2
Imbruvica
PPharmacyclics LLC.
Phase 2
Ukoniq
TTG Therapeutics, Inc.
Phase 2
BRIUMVI
TTG Therapeutics, Inc.
Phase 2
Chantix
PPrism Pharmaceuticals
Phase 2
Zelhou
Jiangsu Simcere Pharmaceutical Co., Ltd.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma4 trials
Breast Cancer1 trial
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Completed·—·Phase 1·NCT02632071·17 enrolled
Relapse1 trial
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Active, not recruiting·—·Phase 1·NCT02787369·3 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ACY-1215. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company